Pregnancy Clinical Trial
— BUPOfficial title:
A Randomized Double-blinded Trial of the Effects of Bupivacaine Induced Motor Blockade on the Second Stage of Labor
Verified date | August 2020 |
Source | University of Texas Southwestern Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The aim of this study is to measure the effects of bupivacaine administered via epidural
catheters on indices of motor blockade ascertained during the second stage of labor. This is
a randomized, double-blind, controlled trial designed to address the primary research
question: Does bupivacaine lengthen the second stage of labor? The secondary research
question is: Is there other evidence of motor blockade attributable to bupivacaine during the
second stage of labor?
The investigators know from prior studies that the length of the second stage in nulliparous
women delivered at Parkland Hospital without epidural analgesia is 28 minutes. The
investigators hypothesize in this now proposed study that epidural analgesia with bupivacaine
will significantly increase this baseline from 28 minutes to 37 minutes or more (a 33%
increase) thus implicating motor blockade. Baseline data for the Bromage and Breen scores
during the second stage as well as the uterine contractility data are not available as these
indices of motor blockade have not here-to-fore been studied in this context.
Currently at Parkland Hospital, 82% of nulliparous women undergoing induction of labor at
term receive continuous epidural infusions with bupivacaine during the first and second
stages of labor. Such women will be identified when admitted for scheduled inductions at
Parkland. After informed consent is obtained standard management of labor induction will be
provided. Those consented women reaching 8 cm cervical dilation will be randomized. Group I
will receive bupivacaine plus fentanyl via epidural catheter during the second stage (i.e. 10
cm dilation) and Group II will receive only fentanyl infusion via epidural catheter (see
study procedure below). Both the patient and the caregiver will be blinded as to whether the
patient is in the bupivacaine plus fentanyl arm or the fentanyl only arm. To detect a 33%
increase (from 28 minutes to 37 minutes) in the primary outcome the investigators need a
total of 310 women enrolled in the study (or 155 per arm). Assuming a 30% consent rate and
given that approximately 1000 women meet the inclusion criteria each year at Parkland, the
investigators project that this study could be completed in 12 months.
Status | Completed |
Enrollment | 481 |
Est. completion date | July 2013 |
Est. primary completion date | July 2012 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 16 Years to 44 Years |
Eligibility |
Inclusion Criteria: - Nulliparous women at 37 weeks gestation or greater. - Scheduled for induction of labor for any indication, to include hypertensive disorders, diabetes, decreased fetal motion, or prolonged pregnancy. - Single without known malformations. - Maternal age > or equal to 16 years. - ASA classification 1 or 2. Exclusion Criteria: - Women who refuse epidural analgesia. - Women with contraindications to epidural analgesia, i.e., severe thrombocytopenia. - Any renal disease with serum creatinine > 1.0 mg/dL. - Allergy to bupivacaine or fentanyl. - Known liver disease such as hepatitis. - Known contraindications to internal electronic fetal monitoring i.e., active herpes, maternal HIV seropositivity. |
Country | Name | City | State |
---|---|---|---|
United States | Parkland Health and Hospital System | Dallas | Texas |
Lead Sponsor | Collaborator |
---|---|
University of Texas Southwestern Medical Center |
United States,
Craig MG, Grant EN, Tao W, McIntire DD, Leveno KJ. A randomized control trial of bupivacaine and fentanyl versus fentanyl-only for epidural analgesia during the second stage of labor. Anesthesiology. 2015 Jan;122(1):172-7. doi: 10.1097/ALN.000000000000045 — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The Duration of the Second Stage of Labor | The length of the second stage of labor (measured as minutes a parturient spends in Stage II) in nulliparous women received a epidural bupivacaine plus fentanyl or fentanyl alone. | Duration of second stage of labor approximately 30 minutes to 150 minutes | |
Secondary | Local Anesthetic Motor Blockade Indices During Stage II of Labor | Motor blockade will be estimated using Bromage and Breen scores (measured on a 6-point standardized scale, 1= Unable to more feet, 6= Able to perform partial knee bend) that estimate motor blockade. This scoring system is based upon the laboring womans' ability to move her lower extremities. | Duration of second stage of labor approximately 30 minutes to 150 minutes | |
Secondary | Mode of Delivery in Women Randomized to Bupivacaine vs. No Bupivacaine During the Second Stage of Labor | At the time of Delivery | ||
Secondary | Number of Participants Whose Newborns Received an APGAR Score of <=3 at 1 Min | Number of participants whose newborns received an APGAR score of <=3 at 1 min. A lower APGAR score represents poor health or a worsening in the Outcome, | At the time of Delivery, up to 3 hours | |
Secondary | Number of Participants Whose Newborns Received an APGAR Score of <=3 at 5 Min | Number of participants whose newborns received an APGAR score of <=3 at 5 minutes. A lower APGAR score represents poor health or a worsening in the Outcome | At the time of Delivery, up to 3 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03442582 -
Afluria Pregnancy Registry
|
||
Terminated |
NCT02161861 -
Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study
|
N/A | |
Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
Enrolling by invitation |
NCT05415371 -
Persistent Poverty Counties Pregnant Women With Medicaid
|
N/A | |
Completed |
NCT04548102 -
Effects of Fetal Movement Counting on Maternal and Fetal Outcome Among High Risk Pregnant Woman
|
N/A | |
Completed |
NCT03218956 -
Protein Requirement During Lactation
|
N/A | |
Completed |
NCT02191605 -
Computer-delivered Screening & Brief Intervention for Marijuana Use in Pregnancy
|
N/A | |
Completed |
NCT02223637 -
Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry
|
||
Recruiting |
NCT06049953 -
Maternal And Infant Antipsychotic Study
|
||
Completed |
NCT02577536 -
PregSource: Crowdsourcing to Understand Pregnancy
|
||
Not yet recruiting |
NCT06336434 -
CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05412238 -
Formulation and Evaluation of the Efficacy of Macro- and Micronutrient Sachets on Pregnant Mothers and Children Aged 6-60 Months
|
N/A | |
Not yet recruiting |
NCT04786587 -
Alcohol Self-reporting During Pregnancy. AUTOQUEST Study.
|
||
Not yet recruiting |
NCT05028387 -
Telemedicine Medical Abortion Service Using the "No-test" Protocol in Ukraine and Uzbekistan.
|
||
Completed |
NCT02783170 -
Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women
|
Phase 4 | |
Completed |
NCT02683005 -
Study of Hepatitis C Treatment During Pregnancy
|
Phase 1 | |
Recruiting |
NCT02507180 -
Safely Ruling Out Deep Vein Thrombosis in Pregnancy With the LEFt Clinical Decision Rule and D-Dimer
|
||
Recruiting |
NCT02619188 -
Nutritional Markers in Normal and Hyperemesis Pregnancies
|
N/A | |
Recruiting |
NCT02564250 -
Maternal Metabolism and Pregnancy Outcomes in Obese Pregnant Women
|
N/A | |
Completed |
NCT02408315 -
Induction With Misoprostol: Oral Mucosa Versus Vaginal Epithelium (IMPROVE)
|
Phase 3 |